As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that policymakers set clear elimination targets for hepatitis B, coordinate efforts, enhance surveillance, and create supportive regulatory environments to support this.

A federal vaccine advisory committee this week is expected to discuss whether newborns should still get the hepatitis B vaccine — the first shot found to prevent cancer.

The Vaccine Integrity Project’s evidence review of the first dose of the hepatitis B vaccine will offer a transparent, data-driven view of its safety and effectiveness,” Michael Osterholm writes.

Robert F. Kennedy Jr.'s vaccine advisers will vote this week on whether to delay hepatitis B shots for most American children, the new chair of the committee said, a move that would be the most consequential change since the health secretary began remaking vaccine policy.

The new chair of the Advisory Committee on Immunization Practices said the panel plans to vote to end universal hepatitis B vaccination at birth and to scrutinize if childhood shots cause allergies.